Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

BACKGROUND: Dupilumab, a fully human monoclonal antibody that binds IL‐4Rα and inhibits signaling of both IL‐4 and IL‐13, has shown efficacy across multiple diseases with underlying type 2 signatures and is approved for treatment of asthma, atopic dermatitis, and chronic sinusitis with nasal polypos...

Descripción completa

Detalles Bibliográficos
Autores principales: Le Floc’h, Audrey, Allinne, Jeanne, Nagashima, Kirsten, Scott, George, Birchard, Dylan, Asrat, Seblewongel, Bai, Yu, Lim, Wei Keat, Martin, Joel, Huang, Tammy, Potocky, Terra B., Kim, Jee H., Rafique, Ashique, Papadopoulos, Nicholas J., Stahl, Neil, Yancopoulos, George D., Murphy, Andrew J., Sleeman, Matthew A., Orengo, Jamie M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
ORIGINAL ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317958/
https://www.ncbi.nlm.nih.gov/pubmed/31838750
http://dx.doi.org/10.1111/all.14151

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7317958/
https://www.ncbi.nlm.nih.gov/pubmed/31838750
http://dx.doi.org/10.1111/all.14151

Ejemplares similares